http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1562972-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28844283e3317d90d610b7f3fb6bf196
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-249
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08
filingDate 2003-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12f13a29f6fa2e7120db94bbba560849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39871aee853491e7a2ab554f12370bca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2901b83119c3d09babd25e249571c613
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ed803c56b4aa0fcc10fa16c16bf4207
publicationDate 2005-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1562972-A2
titleOfInvention ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
abstract The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 205, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
priorityDate 2002-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004092219-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02060919-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395485
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394213
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395486
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395791
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398685
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395685
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414557
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128871932
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128793030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128855025
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1188
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6140
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3120
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6305
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4640
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128094727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID773
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409442
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128053003
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25465
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399539
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6335613
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID724
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6106
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395985
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5366546
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395986
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399947
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399382
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399383
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136046180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6249
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8194
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID857
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398727
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398728
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128530096
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4272
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID791
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136134158
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399946
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135971249
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1148
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136380179
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID27661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID61503
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226452378
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID446541
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226452379
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID81462
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128334456
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44258291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6235
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396525

Total number of triples: 88.